Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

[1]  A. Tan,et al.  Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors , 2013, Cancer Chemotherapy and Pharmacology.

[2]  A. Suttle,et al.  Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer , 2013, Xenobiotica; the fate of foreign compounds in biological systems.

[3]  J. Burke,et al.  Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Schellens,et al.  Moving towards dose individualization of tyrosine kinase inhibitors. , 2011, Cancer treatment reviews.

[5]  H. Klinker,et al.  The Role of Therapeutic Drug Monitoring in the Management of Patients With Human Immunodeficiency Virus Infection , 2011, Therapeutic drug monitoring.

[6]  E. Wiemer,et al.  Drug Transporters and Imatinib Treatment: Implications for Clinical Practice , 2010, Clinical Cancer Research.

[7]  E. Heath,et al.  A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High‐Fat or Low‐Fat Meal in Patients With Advanced Solid Tumors , 2010, Clinical pharmacology and therapeutics.

[8]  M. Rowland,et al.  Pharmacokinetic considerations as to when to use dried blood spot sampling. , 2010, Bioanalysis.

[9]  B. Rini.  Biomarkers: hypertension following anti-angiogenesis therapy. , 2010, Clinical advances in hematology & oncology : H&O.

[10]  G. Sledge,et al.  Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). , 2010 .

[11]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Figlin,et al.  Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Demetri,et al.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis , 2010, Cancer Chemotherapy and Pharmacology.

[14]  J. Nedelman,et al.  A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling Times , 2009, Therapeutic drug monitoring.

[15]  K. Zaman,et al.  Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[16]  E. Merkle,et al.  Phase I Trial of Pazopanib in Patients with Advanced Cancer , 2009, Clinical Cancer Research.

[17]  R. Berardi,et al.  Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  W. Cacheux,et al.  Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  P. A. Harris,et al.  Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. , 2008, Journal of medicinal chemistry.

[20]  E. Voest,et al.  The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. , 2008, Current clinical pharmacology.

[21]  H. Rugo,et al.  Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Sonpavde,et al.  Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma , 2008, Expert opinion on investigational drugs.

[23]  John Smeraglia,et al.  Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins , 2007, Journal of Translational Medicine.

[24]  Ming-Chih Crouthamel,et al.  Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity , 2007, Molecular Cancer Therapeutics.

[25]  D. McDonald,et al.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.

[26]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. Raymond,et al.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Janvier,et al.  Role of vascular endothelial growth factor receptor 1 and vascular endothelial growth factor receptor 2 in the vasodilator response to vascular endothelial growth factor in the neonatal piglet lung , 2005, Critical care medicine.

[29]  A. D. de Vos,et al.  KDR (VEGF Receptor 2) Is the Major Mediator for the Hypotensive Effect of VEGF , 2002, Hypertension.

[30]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.